Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04474288 · ClinicalTrials.gov registry record
The COVID-19 PUI Reality Check (CPRC) Study
A clinical trial of Covid19 Immunology, sponsored by Bassett Healthcare.
- Completed
- Registry status
- 37
- Enrollment target
- 1
- Study location
NCT04474288: Completed study of Covid19 Immunology, sponsored by Bassett Healthcare.
NCT04474288 is a study of Covid19 Immunology that has completed, run by Bassett Healthcare. The registered enrollment target is 37 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04474288, a study of Covid19 Immunology, has completed, sponsored by Bassett Healthcare.
- COMPLETED
- Registry status
- 37 participants
- Enrollment target
- 1
- Study location
Study Summary
This study compares SARS-CoV-2 immune responses in high pretest probability swab negative hospitalized PUI patients vs. low pretest probability swab negative hospitalized APS (Asymptomatic Persons being Screened) patients to try to understand the appropriateness and safety of clinical decisions made in these patient populations based on swab results.
Primary Outcome
Qualitative seroconversion response rates (RR) in NP SARS-CoV-2 PCR swab negative PUI vs. swab negative APS patients will be compared as the primary outcome measurement.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST SARS-CoV-2 antibody testing
Study Locations (1)
New York
- Bassett Medical Center - Cooperstown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2020-07-16 |
| Est. Completion | 2022-02-28 |
What the finished NCT04474288 record still lists
NCT04474288 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 37 participants, a relatively small participant target.
The record links to 1 condition, with Covid19 Immunology appearing as the primary indexed condition, and to 1 intervention - of which SARS-CoV-2 antibody testing is the first listed.
NCT04474288 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT04474288 about?
NCT04474288 is a clinical study titled "The COVID-19 PUI Reality Check (CPRC) Study". This study compares SARS-CoV-2 immune responses in high pretest probability swab negative hospitalized PUI patients vs. low pretest probability swab negative hospitalized APS (Asymptomatic Persons being Screened) patients to try to understand the appropriateness and safety of clinical decisions made...
What is the current status of trial NCT04474288?
This trial is currently completed. The enrollment target is 37 participants. The study started on 2020-07-16. Estimated completion is 2022-02-28.
What conditions does trial NCT04474288 study?
This clinical trial studies the following conditions: Covid19 Immunology.
What interventions are being tested in trial NCT04474288?
The interventions under investigation include: SARS-CoV-2 antibody testing (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04474288?
This trial is sponsored by Bassett Healthcare, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04474288 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02800486 · 37 participants · Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- NCT03173937 · 37 participants · Phase 1
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- NCT03295227 · 37 participants · Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
- NCT03401047 · 37 participants · Early Phase 1
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI